Ayed O Ayed

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3943911/publications.pdf

Version: 2024-02-01

10 papers	229 citations	1307366 7 h-index	9 g-index
10	10	10	630 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Ruxolitinib as firstâ€ine treatment in secondary hemophagocytic lymphohistiocytosis: A second experience. American Journal of Hematology, 2018, 93, E123-E125.	2.0	39
2	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	4.2	65
3	Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leukemia and Lymphoma, 2018, 59, 2287-2296.	0.6	4
4	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer Journal, 2018, 8, 63.	2.8	22
5	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with doseâ€adjusted EPOCH plus rituximab. American Journal of Hematology, 2017, 92, 1156-1162.	2.0	8
6	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	0.6	2
7	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. Blood, 2016, 128, 5322-5322.	0.6	O
8	Interobserver Variability of Mitotic Index and Utility of PHH3 for Risk Stratification in Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology, 2015, 143, 385-392.	0.4	28
9	Immunotherapy for multiple myeloma: Current status and future directions. Critical Reviews in Oncology/Hematology, 2015, 96, 399-412.	2.0	25
10	Relationship of serum imatinib trough level and response in CML patients: Long term follow-up. Leukemia Research, 2010, 34, 1573-1575.	0.4	36